Chondrosarcoma Clinical Trial
Official title:
S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with
meningeal tumors that have recurred or that cannot be removed surgically.
OBJECTIVES:
- Estimate failure free survival, overall survival, and response in patients with
residual or recurrent/progressive aggressive meningeal tumors (malignant meningioma,
hemangiopericytoma, and primary nervous system sarcoma) treated with ifosfamide.
- Evaluate toxicities of ifosfamide in this patient population.
OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each
21 day treatment course. Patients are evaluated for response/progression after every 2
courses. Patients with stable disease receive up to 8 courses of therapy. Treatment
continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year, then every 6 months thereafter.
PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039801 -
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
| Recruiting |
NCT06029218 -
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
|
N/A | |
| Recruiting |
NCT04040205 -
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
|
Phase 2 | |
| Not yet recruiting |
NCT06029478 -
Understanding Engagement Trends in Chondrosarcoma Clinical Trials
|
||
| Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
| Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
| Active, not recruiting |
NCT04521686 -
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
|
Phase 1 | |
| Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
| Completed |
NCT02496741 -
Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Terminated |
NCT00543712 -
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
|
Phase 2 | |
| Recruiting |
NCT05861245 -
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
|
N/A | |
| Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
| Recruiting |
NCT04278781 -
AG-120 in People With IDH1 Mutant Chondrosarcoma
|
Phase 2 | |
| Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
| Recruiting |
NCT04673942 -
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT01609179 -
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
|
N/A | |
| Completed |
NCT01560260 -
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
|
Phase 2 | |
| Recruiting |
NCT06387485 -
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
|
N/A |